INTEC PHARMA LTD. (NASDAQ:NTEC) Files An 8-K Other Events
On December 11, 2019, Intec Pharma Ltd. issued a press release titled “Intec Pharma Provides Update on Novartis Feasibility and Option Agreement”. A copy of the press release is filed as Exhibit 99.1 hereto and is incorporated herein by reference.
Intec Pharma Ltd. Exhibit
EX-99.1 2 f8k121119ex99-1_intecpharma.htm PRESS RELEASE ISSUED BY INTEC PHARMA LTD. ON DECEMBER 11,…
To view the full exhibit click
About INTEC PHARMA LTD. (NASDAQ:NTEC)
Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs. The Company is focusing on the clinical development program for the Phase III clinical study of the Accordion Pill Carbidopa Levodopa (AP-CDLD), for the treatment of advanced stages Parkinson’s disease patients. Its pipeline also comprises The Accordion Pill-Zaleplon, a drug for sleep onset, which is in Phase II clinical program. Furthermore under research is Accordion Pill-Undisclosed Drug for the prevention and treatment of small bowel non-steroidal anti-inflammatory drug (NSAID) induced ulcers.